Cisplatin radiosensitization (concurrent with EBRT + brachytherapy)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-CISPLATIN`

ID	`REG-CISPLATIN-RADIOSENS`
Type	Regimen
Status	reviewed 2026-04-26 \| pending_clinical_signoff
Diseases	None declared
Sources	`SRC-ESMO-CERVICAL-2024` `SRC-NCCN-CERVICAL-2025`

Notes

Concurrent CRT for FIGO IB3-IVA cervical: EBRT 45-50.4 Gy / 25-28 fx + cisplatin weekly + brachytherapy boost (24-30 Gy HDR equivalent). RT dose, fractionation, and brachytherapy are NOT modellable in current OpenOnco schema — see PROPOSAL §17. This regimen entry captures the cisplatin-only chemo backbone.

Used By

Algorithms

ALGO-VULVAR-VAGINAL-SCC-1L - ALGO-VULVAR-VAGINAL-SCC-1L

Disease

DIS-VULVAR-VAGINAL-SCC - Vulvar and vaginal squamous cell carcinoma

Indication

IND-CERVICAL-LOCALLY-ADVANCED-CRT - IND-CERVICAL-LOCALLY-ADVANCED-CRT
IND-VULVAR-VAGINAL-SCC-LA-1L-CISPLATIN-RT - IND-VULVAR-VAGINAL-SCC-LA-1L-CISPLATIN-RT